StreetInsider.com News Articles

Form 424B7 Adlai Nortye Ltd.

Mon, 20 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26787985.html

Form 424B7 Adlai Nortye Ltd.

Mon, 20 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26787985.html

Form 6-K Adlai Nortye Ltd. For: Jul 16

Fri, 17 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26781469.html

Form 6-K Adlai Nortye Ltd. For: Jul 16

Fri, 17 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26781469.html

Adlai Nortye doses first patient in weekly arm of AN9025 trial

Thu, 16 Jul 2026 07:00:24 -0400

Adlai Nortye Ltd. (NASDAQ: ANL) announced that the first patient has been dosed in the United States in the intermittent weekly dosing arm of its ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor, according to a press release.

The Phase 1 study is a first-in-human, multicenter, open-label trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. Both the daily dosing and weekly dosing arms are now enrolling.

The trial is being conducted by Adlai Nortye in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. under a license agreement.

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in the intermittent weekly dosing (QW) arm

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Sawhney Roger

Wed, 15 Jul 2026 10:33:00 -0400

si-local-file:///var/storage/secattach/20260715/26772491.html

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Sawhney Roger

Wed, 15 Jul 2026 10:33:00 -0400

si-local-file:///var/storage/secattach/20260715/26772491.html

Adlai Nortye adds two oncologists to scientific advisory board

Mon, 13 Jul 2026 07:00:52 -0400

Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology company, has appointed Dr. David S. Hong and Dr. Piro Lito to its Scientific Advisory Board, according to a company statement.

Dr. Hong serves as the Douglas E. Johnson Endowed Professor and Deputy Chair in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He received his M.D. from Albert Einstein College of Medicine and completed his oncology fellowship at MD Anderson. He has authored hundreds of peer-reviewed publications and received awards including the Amgen Young Investigator Award and the Jesse H. Jones Award.

Dr. Lito holds the

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400

SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.

“Adlai Nortye's pipeline is anchored by its RAS inhibitor programs, including AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody drug conjugate (ADC) leveraging our RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, alongside our tri-specific immuno-oncology candidate AN8025.

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400

Cantor Fitzgerald Starts Adlai Nortye Ltd. (ANL) at Overweight

Mon, 22 Jun 2026 06:13:52 -0400

(Updated - June 22, 2026 6:13 AM EDT)

Cantor Fitzgerald analyst Li Watsek initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Overweight rating.

The analyst commented: "We are initiating coverage of Adlai Nortye Ltd. (ANL) with an Overweight rating. Adlai has turned its focus to the RAS pathway in metastatic pancreatic ductal adenocarcinoma (mPDAC), leading with its Ph1 panRAS (ON) inhibitor, AN9025. The stock had a great run YTD, up 700% vs. 10% for XBI (one of the best-performing biotech stocks YTD), but we believe shares are worth $28/sh, implying a further ~180% upside."

For an analyst ratings summary and ratings

Cantor Fitzgerald Starts Adlai Nortye Ltd. (ANL) at Overweight

Mon, 22 Jun 2026 06:13:52 -0400

(Updated - June 22, 2026 6:13 AM EDT)

Cantor Fitzgerald analyst Li Watsek initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Overweight rating.

For an analyst ratings summary and ratings

Form 4 Adlai Nortye Ltd. For: Dec 16 Filed by: Ji Ping

Wed, 10 Jun 2026 12:21:00 -0400

si-local-file:///var/storage/secattach/20260610/26628832.html

Form 4 Adlai Nortye Ltd. For: Dec 16 Filed by: Ji Ping

Wed, 10 Jun 2026 12:21:00 -0400

si-local-file:///var/storage/secattach/20260610/26628832.html

Form 3 Adlai Nortye Ltd. For: May 28 Filed by: Ye Xiaofeng

Mon, 01 Jun 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260601/26581092.html

Form 3 Adlai Nortye Ltd. For: May 28 Filed by: Ye Xiaofeng

Mon, 01 Jun 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260601/26581092.html

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Tse Alan Ming Lun

Thu, 28 May 2026 21:46:00 -0400

si-local-file:///var/storage/secattach/20260528/26569502.html

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Tse Alan Ming Lun

Thu, 28 May 2026 21:46:00 -0400

si-local-file:///var/storage/secattach/20260528/26569502.html

Oppenheimer Starts Adlai Nortye Ltd. (ANL) at Outperform

Thu, 28 May 2026 06:32:34 -0400

Oppenheimer analyst Jay Olson initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Outperform rating and a price target of $32.00.

The analyst comments "We initiate coverage of Adlai Nortye (ANL) with an Outperform rating and a $32 PT, reflecting our optimism around its key assets and broader R&D capabilities. While ANL shares are up +770% YTD (vs. NBI: +9%), driven primarily by favorable read-through to AN9025 from RVMD's updates, for good reason, we continue to see meaningful upside from both AN9025 and the broader pipeline, particularly with AN4035, a novel pan-RAS(ON)i-conjugated antibody. Indeed, AN4035 could be the first US